Monopar Therapeutics’ (MNPR) Buy Rating Reiterated at BTIG Research

BTIG Research restated their buy rating on shares of Monopar Therapeutics (NASDAQ:MNPR) in a research note released on Monday,Benzinga reports. They currently have a $104.00 price target on the stock.

Several other brokerages have also commented on MNPR. Weiss Ratings reiterated a “sell (d-)” rating on shares of Monopar Therapeutics in a research note on Thursday, January 22nd. Chardan Capital reaffirmed a “buy” rating and set a $100.00 price objective on shares of Monopar Therapeutics in a report on Thursday, January 29th. Leerink Partners started coverage on Monopar Therapeutics in a research report on Monday, November 10th. They set an “outperform” rating and a $115.00 target price on the stock. Morgan Stanley began coverage on Monopar Therapeutics in a report on Friday, January 9th. They issued an “overweight” rating and a $115.00 target price for the company. Finally, Raymond James Financial cut Monopar Therapeutics from a “strong-buy” rating to an “outperform” rating and decreased their target price for the company from $142.00 to $123.00 in a research report on Friday, November 14th. Two research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $107.00.

Monopar Therapeutics Stock Down 3.5%

MNPR stock opened at $55.62 on Monday. The business has a 50 day moving average price of $64.08 and a 200 day moving average price of $67.48. The stock has a market cap of $371.54 million, a price-to-earnings ratio of -16.17 and a beta of 1.52. Monopar Therapeutics has a fifty-two week low of $26.06 and a fifty-two week high of $105.00.

Insiders Place Their Bets

In related news, CFO Quan Anh Vu bought 1,500 shares of the stock in a transaction on Friday, December 26th. The shares were bought at an average cost of $69.95 per share, for a total transaction of $104,925.00. Following the purchase, the chief financial officer owned 1,500 shares of the company’s stock, valued at $104,925. This trade represents a ∞ increase in their position. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 20.50% of the company’s stock.

Hedge Funds Weigh In On Monopar Therapeutics

Institutional investors have recently bought and sold shares of the company. Wellington Management Group LLP acquired a new stake in shares of Monopar Therapeutics in the 3rd quarter worth $18,904,000. Siren L.L.C. purchased a new stake in Monopar Therapeutics in the 4th quarter valued at approximately $13,863,000. Deerfield Management Company L.P. acquired a new position in Monopar Therapeutics during the 3rd quarter worth approximately $13,048,000. RA Capital Management L.P. raised its stake in shares of Monopar Therapeutics by 30.5% during the 4th quarter. RA Capital Management L.P. now owns 667,207 shares of the company’s stock worth $43,569,000 after buying an additional 156,000 shares in the last quarter. Finally, TCG Crossover Management LLC purchased a new position in shares of Monopar Therapeutics during the 3rd quarter worth approximately $12,496,000. 1.83% of the stock is owned by institutional investors and hedge funds.

About Monopar Therapeutics

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.